Gritstone Bio Inc (GRTS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GRTS Annual Cash Flow →
This page allows investors to follow Gritstone Bio Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2024)
6 Months
(Mar 31 2024) (Dec 31 2023) (Sep 30 2023) (Jun 30 2023)
Operating Activities
Income-63.78
Depreciation & amortization3.35
Amortization of Other Assets0.77
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation6.71
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-4.81
Increase Decrease In Deposit And Other Assets Current-
Warrant Issuance In Conjunction With License Agreement-
Operating Lease Cost-
Increase Decrease In Lease Liability-6.30
Increase Decrease In Accrued And Other Liabilities Non Current-0.38
Increase Decrease In Operating Lease Right Of Use Assets-
Noncash Operating Lease Expense6.61
Increase Decrease In Contract With Customer Liability-1.65
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities-4.09
Increase (Decrease) in Accounts Payable0.06
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.14
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.98
Discontinued operations0.00
Net Cash flow from Operating Activities-60.38
Investing Activities
Capital Expenditures-0.18
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.14
Payments to Acquire Marketable Securities-3.08
Real Estate Investments0.00
Proceeds From Maturity Of Marketable Securities14.54
Proceeds From Sale Of Marketable Securities-
Prepayments On Financing Lease-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities11.42
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-2.21
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock5.64
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-39.06
Payment For Deferred Ipo Costs-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs-
Payments Of Financing Lease-0.12
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents70.58
Capital Expenditures Incurred But Not Yet Paid0.03
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction0.39
Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities35.25
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-60.55
Total Cash Flow-13.71
4 historic quarters locked

Sign in to unlock the full Gritstone Bio Inc cash flow history.

About Gritstone Bio Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-096211

Figures are derived from filed reports and may be restated. Historical data is subject to revision.